Deciphering, communicating, and engineering the CRISPR PAM

Ryan T. Leenay and Chase L. Beisel*

North Carolina State University

Department of Chemical and Biomolecular Engineering

Raleigh, NC 27695-7905

*Correspondence to cbeisel@ncsu.edu (C.L.B.)

Keywords: Cas9, Cpf1, CRISPR-Cas systems, PFS, rPAM

1 **ABSTRACT**

2 Clustered regularly interspaced short palindromic repeat (CRISPR) loci and their flanking
3 CRISPR-associated (*cas*) genes make up RNA-guided, adaptive immune systems in prokaryotes
4 whose effector proteins have become powerful tools for basic research and biotechnology. While
5 the Cas effector proteins are remarkably diverse, they commonly rely on protospacer-adjacent
6 motifs (PAMs) as the first step in target recognition. PAM sequences are known to vary
7 considerably between systems and have proven to be difficult to predict, spurring the need for
8 new tools to rapidly identify and communicate these sequences. Recent advances have also
9 shown that Cas proteins can be engineered to alter PAM recognition, opening new opportunities
10 to develop CRISPR-based tools with enhanced targeting capabilities. In this review, we discuss
11 the properties of the CRISPR PAM and the emerging tools for determining, visualizing, and
12 engineering PAM recognition. We also propose a standard means of orienting the PAM to
13 simplify how its location and sequence are communicated.

Introduction

Over the past 11 years, CRISPR (Clustered Regularly Interspaced Palindromic Repeats) loci and their associated Cas (CRISPR-associated) proteins have transitioned from curious prokaryotic immune systems to revolutionary tools for fundamental biomolecular research, biotechnology, agriculture, and medicine [1–5]. A key driver has been the ease by which the effector proteins of these systems can be utilized as programmable nucleases to specifically bind and/or cleave selected DNA or RNA sequences. Because these proteins and their guide RNAs are easier and cheaper to implement than all comparable technologies, CRISPR technologies have become a standard for applications in genome editing, gene regulation, and DNA imaging and are being explored for gene drives and sequence-specific antimicrobials [6–16]. CRISPR-Cas immune systems have also proven to be remarkably diverse, with new and emerging systems poised to further advance existing applications or drive entirely new ones [17–20]. Despite this diversity, CRISPR-Cas systems rely on a common set of rules for target recognition: complementary between the guide RNA and the target sequence, and a protospacer-adjacent motif (PAM) flanking the target [21–29]. This review details the nature of the PAM and recent efforts to identify, disseminate, and alter the recognized PAM sequences for different CRISPR-Cas systems. We describe the field's current understanding of what defines a PAM as well as available methods to identify and communicate these sequences. We also discuss efforts to re-engineer PAM recognition and generate CRISPR-Cas systems with altered or improved DNA recognition capabilities.

CRISPR Biology

CRISPR-Cas systems naturally function as adaptive immune systems that protect bacteria and

archaea from foreign genetic material such as bacteriophages or plasmids. The ability to uniquely recognize foreign sequences stems from the CRISPR array, a short stretch of DNA composed of alternating conserved repeats and target-specific spacers [1,30–32]. Each spacer is directly acquired from a fragment of the foreign genetic material called the protospacer, allowing the CRISPR array to possess heritable memory of the infection [30]. The CRISPR array is transcribed and subsequently processed into individual units called CRISPR RNAs (crRNAs) [33–35]. These RNAs associate with the system's Cas effector proteins to form a ribonucleoprotein surveillance complex. Once assembled, the complex scans the cell for PAM sequences. Upon binding, the complex interrogates the extent of base pairing between the downstream sequence and the spacer portion of the crRNA. Extensive base pairing leads to the Cas proteins cleaving or degrading the target sequence, resulting in the clearance of the foreign invader.

CRISPR-Cas systems possess a diverse compilation of genes and are found throughout the prokaryotic world. Current estimates place CRISPR-Cas systems within ~50% of bacterial genomes and ~90% of archaeal genomes [18], although recent metagenomics sequencing analyses have suggested that the frequency of CRISPR-Cas systems in nature could be much lower [36]. Furthermore, only a subset of the identified systems may be active. Roughly 100 protein families have been associated with these systems, where the varying prevalence and co-occurrence of these genes has spurred the development of numerous classification schemes [18,19,37,38]. The most recent scheme breaks the systems into two classes, six types, and 19 subtypes [18,19]. The two classes are differentiated by whether a protein complex (Class 1) or individual protein (Class 2) serves as the effector of immune surveillance. The six types (I - VI) are defined by the presence of a signature gene encoding a protein responsible for nucleic-acid

cleavage (e.g. Cas3 for Type I systems, Cas9 for Type II systems). The types also differ in their mechanisms of crRNA processing and target recognition, as well as whether the target is DNA (Types I, II, V), RNA (Type VI), or both (Type III) [39,40]. The subtypes are named by addition of a letter to the type (e.g. I-A, II-C) and are defined based on the specific *cas* genes and their configuration. As the vast expanse of CRISPR-Cas systems in the prokaryotic world remain poorly characterized, more unique functions and systems are expected to be discovered and will ultimately yield new CRISPR tools and technologies.

PAM Characteristics

The PAM was first observed in 2008, when Horvath and coworkers noticed conserved sequences that flanked protospacers acquired by *Streptococcus thermophilus* after being challenged with a lytic bacteriophage [21,22]. The following year, Mojica and coworkers uncovered similar motifs for multiple CRISPR-Cas systems through bioinformatics analyses, which established PAMs as generalized features of these systems [23]. Each report coined different names for these motifs—CRISPR motifs or protospacer-adjacent motifs (PAMs), respectively--where the latter became the accepted terminology.

The first insights into the function of these motifs first came from studies of the Type III CRISPR-Cas system in *Staphylococcus epidermidis* by Marraffini and Sontheimer, who demonstrated that these flanking sequences are essential for self/non-self discrimination (**Figure 1**) [41]. They specifically showed that the system uses these flanking sequences to differentiate between the CRISPR array (self) and the foreign invader (non-self), which both harbor a sequence perfectly complementary to the CRISPR RNA spacer. While the mechanism of discrimination appeared to rely on base pairing between the flanking regions of the spacer and protospacer [41], it established the theme that flanking sequences such as PAMs are critical for

protospacer selection and target recognition. This insight was upheld as others showed that the PAM was an essential element for target recognition and cleavage [9,42].

Extensive structural and biochemical analyses have helped reveal how the PAM participates in target recognition [43–47]. Cas effector proteins directly bind the PAM sequence through protein-DNA interactions and subsequently unzip the downstream DNA sequence. The effector proteins then interrogate the extent of base pairing between one strand of the DNA target and the spacer portion of the CRISPR RNA. Sufficient complementarity between the two drives target cleavage. Critically, if a PAM sequence is absent, the effector proteins do not interrogate the downstream sequence even if it is perfectly complementary to the spacer. We refer to this unrecognized sequence as a non-PAM. Aside from its function in immune recognition, the PAM also plays an integral role on spacer acquisition. In this case, the acquisition proteins alone or in coordination with effector proteins recognize defined PAM sequences while acquiring new spacers, ensuring that each new spacer can recognize the invading DNA [48–53]. As PAMs for acquisition and interference can be different [29,54,55], the associated sequences have been respectively termed spacer acquisition motifs (SAMs) and target interference motifs (TIMs) [56,57]. While this distinction is important, we refer to both motifs as PAMs given our primary focus on immune defense and the limited adoption of the terms SAMs and TIMs.

Despite the common role of the PAM in target recognition, its characteristics vary between the different types of CRISPR-Cas systems. One major difference is the location of the PAM. Using the non-target strand of the protospacer as a reference, the PAM is located on the 5' of the protospacer for Type I and V systems and on the 3' end of the protospacer for Type II systems. Note that the target strand also has been used to specify the PAM [29,43,58,59], creating some confusion about the exact location and sequence of any reported PAM; see **Box 1**

and **Figure 2** for more information on these orientations and why we recommend the guide-centric orientation used in this review. **Figure 3** illustrates the location of the PAM for different CRISPR-Cas system types given this orientation. In the case of Type III and Type VI systems, limited evidence suggests that the PAM is located within the target RNA [39,40]. Because of this unique location, the PAM for these systems was renamed the RNA PAM (rPAM) or the protospacer-flanking sequence (PFS), respectively. Given that Type III systems are thought to rely on base pairing between the crRNA 5' handle and the region flanking the target DNA sequence [41], more work is needed to determine whether this mechanism or the rPAM is normally implemented and whether they occur separately or together.

Aside from location, the composition of the PAM can vary widely. The composition includes the sequences comprising the PAM, the length of the linker (represented by N's, where N any one of the four possible bases) separating the protospacer and the sequence-specific portion of the PAM, and the promiscuity in deviating from a defined consensus sequence. As one example, the widely used Type II-A system from *Streptococcus pyogenes* recognizes a NGG PAM, and to a lesser extent, an NAG PAM [9,23,60]. Separately, one Type II-A system from *Streptococcus thermophilus* recognizes an NNAGAA PAM but has the ability to recognize other sequences such as NNGGAAA and may accommodate changes in its linker length of 2 nucleotides [21,22,61,62]. Finally, the Type I-E system from *Escherichia coli* has one of the most promiscuous PAM recognition capabilities, with at least nine recognized PAM sequences (NAAG, NAGG, NATG, NGAG, NTAG, NAAC, NAAA, NAAT, NATA) and a strong nucleotide preference at the N position for some of these PAMs [29,58,63,64]. **Table 1** contains representative consensus sequences for the most active PAMs for each characterized subtype.

Given that PAMs can vary widely even within a given subtype [21–23,65], more work is needed to fully interrogate the diversity of PAMs in nature.

PAM Determination

The PAM is an essential feature of CRISPR-Cas systems, whether for the biological function of the system or for harnessing the system as a biomolecular tool. Determining the full set of functional PAM sequences, however, has proven difficult. This challenge has spurred the development of multiple methods to determine PAMs (**Figure 4**). Below we describe the available methods along with their particular advantages and disadvantages. While all of these methods reproduce the same highly active PAM sequences, they can often identify differing sub-optimal PAMs, which can impact target selection and off-target predictions. Thus, the best option for PAM determination will likely depend on the particular CRISPR-Cas system and its end use.

Protospacer identification in silico

Mojica and coworkers introduced the first means of identifying PAMs as part of their original observation of this motif [23]. Under this method, each spacer sequence from a natural CRISPR array is subjected to a nucleotide BLAST search for homologous sequences [66]. Strong matches that appear to be derived from bacteriophages or plasmids are compiled, and the flanking sequences are aligned to discern a general motif. This method offers a rapid means of identifying potential functional PAM sequences that can be evaluated experimentally. With the recent development of automated online tools such as *CRISPRTarget* [67], the analysis can be completed in less than a day. One disadvantage is a strong dependence on available sequencing information, which may not contain the associated invader sequences. Another is the challenge

of deciding whether a BLAST hit represents the true source of the spacer, particularly when mismatches are present between the spacer and the putative protospacer sequence. Third, even if the protospacer is the source of the spacer, some of the protospacers may have accumulated mutations in the PAM. Finally, the PAMs associated with acquisition can represent a subset of those that elicit targeting [48,49,68], giving a narrow impression of the PAMs that elicit interference. For these many reasons, the *in silico* method represents a convenient starting point but often lacks sufficient sequence information and is less suited to obtain a comprehensive picture of the PAM for a given system.

Plasmid clearance in vivo

The second and most common method screens for functional PAM sequencing using the natural ability of CRISPR-Cas systems to clear foreign genetic material. This method utilizes an effector protein that is either already present in its native host [59] or is imported into a convenient host such as *Escherichia coli* [60,61,69]. To generate potential PAM sequences, a randomized nucleotide library is inserted next to a target sequence within a plasmid. Plasmids harboring the PAM library are transformed into the host and then subjected to next-generation sequencing. Any plasmids harboring functional PAM sequences would be cleared by the Cas effector proteins, resulting in a substantially lower frequency in the library. This method has been the most widely used because it recapitulates the natural function of CRISPR-Cas systems and has the potential to comprehensively determine all functional PAM sequences. One disadvantage is that the method employs a negative selection, which requires extensive library coverage to identify the missing sequences. Furthermore, because the screen is *in vivo*, there is a general limit on the library size, and the Cas proteins must be functionally expressed in a non-native host. Finally, the readout of this method is the frequency of PAM escape, whether by mutating the

target or by promoting DNA repair. This is problematic particularly for less-active PAM sequences that may translate poorly to other CRISPR-based applications, such as genome editing or gene regulation [54,64,70].

One recent variation on this method generates a library of guide RNAs that tile along the genome of a lytic bacteriophage [39]. The host harboring the CRISPR-Cas system is transformed with the plasmids harboring the guide-RNA library and is then infected with the bacteriophage. Cells survive if the target location on the bacteriophage genome is flanked by a PAM, resulting in the enrichment of guide RNAs targeting functional PAM sequences. This strategy was applied to elucidate the PFS for the RNA-targeting Type VI effector protein C2c2 using the single-stranded RNA bacteriophage MS2 [39]. By selecting for cells targeting protospacers flanked by a functional PFS, the screen provided a positive selection. The major limitations of this variation are that the guide-RNA library is much smaller than the equivalent PAM library, not all possible PAMs may be sufficiently represented within the bacteriophage genome, and guide-RNA libraries will be much more expensive to generate than PAM libraries. Therefore, this strategy offers some unique advantages over the traditional method if a sufficiently large library can be generated and the associated costs are acceptable.

DNA cleavage in vitro

In contrast to the *in vivo* plasmid-clearance methods described above, methods have been developed to determine PAMs under *in vitro* conditions. These methods involve an *in vitro* cleavage reaction that combines purified Cas effector proteins, the *in vitro*-transcribed guide RNAs, and a target DNA library of potential PAM sequences. Following the cleavage reaction, the PAM library is subjected to next-generation sequencing. The reaction can be conducted as a positive screen by ligating adapters to the ends of cleaved library members [70,71], or as a

negative screen by sequencing the intact library members [69]. *In vitro* methods generally offer numerous advantages particularly over *in vivo* methods. For instance, the screened library can be multiple orders-of-magnitude larger for *in vitro* screens than for *in vivo* screens because there are no limitations from transformation efficiencies or cloning *in vitro*. Furthermore, *in vitro* reactions grant exquisite control over the assay conditions, such as component concentrations, reaction temperature, and the reaction time. Finally, the ability to sequence the cleavage products represents a positive screen that can reliably identify functional PAM sequences. One downside is that reconstituting the complete system requires complete knowledge of the required components as well as a protein purification. Another is that the ligation step requires a double-stranded break, which excludes Type I systems that cleave and degrade the target. Finally, assay conditions can deviate from the cellular environment, whether it is the buffer conditions, the relative stoichiometry of Cas effector proteins and targets, or the reaction times. This deviation can yield artificial PAM assignments as recently highlighted when Karvelis and coworkers varied the stoichiometry of Cas9 and the target DNA [71]. These *in vitro* methods thus provide powerful screens to comprehensively determine PAMs for many CRISPR-Cas systems, although the resulting PAMs may not translate well *in vivo*.

DNA binding in vivo

The high-throughput experimental methods described above all relied on target cleavage. However, the ability to generate catalytically-dead Cas effector proteins affords the development of PAM determination methods based on DNA binding [8–10]. We recently reported an *in vivo* DNA-binding method that utilizes catalytically-dead effector proteins to regulate the expression of GFP in *E. coli* [64]. As part of the screen, binding by the catalytically-dead effector proteins blocks expression of the LacI repressor, which would otherwise block expression of GFP. Based

on this configuration, cells harboring a functional PAM sequence fluorescence, allowing these cells to be isolated by fluorescence-activated cell sorting and subjected to next-generation sequencing. The unique benefits of this method include a positive screen based on the expression of GFP only in the presence of a functional PAM, and the ability to tune the assay stringency by titrating in the LacI inhibitor IPTG. One limitation of the method is the need to identify and inactivate the catalytic domains of the desired CRISPR-Cas systems, particularly if the systems have not undergone initial characterization. Another is the size of the limited library size that can be screened akin to any *in vivo* screen. Finally, the absence of nuclease activity can yield PAMs that promote efficient binding but not efficient cleavage, even though the PAMs elucidated to date using this method closely aligned with those determined by cleavage-based methods [61,63,64,69,71–73]. The *in vivo* DNA binding method thus may be best suited for better understanding the biophysics of DNA recognition or in applications centered on DNA binding or gene regulation. PAM determination methods that rely on DNA binding *in vitro* are also under development that could introduce the advantages of *in vitro* screens [74].

PAM Reporting

PAM determination methods often generate a large collection of functional PAM sequences that vary in their extent of enrichment (for positive screens) or depletion (for negative screens). The question is how to best report this information without providing the complete list of all sequences and their associated enrichment or depletion scores. A number of reporting schemes have been described, where each is illustrated in **Figure 5** using published PAM determination data for the widely used Type II-A system from *S. pyogenes* and the well-characterized Type I-E system from *Escherichia coli* [64,72]. As illustrated in this figure, each reporting scheme manages a trade-off between simplicity and information content.

Sequence logos and consensus sequences have been the most common reporting schemes to date starting with the original discovery of the PAM [21,22]. Sequence logos display the conservation of each base within each position: more conserved or highly active bases appear as larger letters, while less conserved or less active bases appear as smaller letters. Consensus sequences report a single sequence that captures the most dominant set of functional PAM sequences. For instance, the consensus sequence for the *S. pyogenes* Cas9 is NGG, while the sequence logo shows a small but notable A in the middle position reflecting partial activity of an NAG PAM [23,60]. Conversely, the consensus sequence for the promiscuous *E. coli* I-E system has been reported as AWG (where W is A or T) while the sequence logo shows other, smaller letters at each of the three positions [23,58]. Both schemes are easy to interpret and can be expanded to any sequence length. However, they also sacrifice individual functional PAM sequences and their relative activity. This loss of information is manageable if the PAMs are simple or only the most active functional PAM sequences are required for the final use of the interrogated CRISPR-Cas system, such as for designing highly active guide RNAs. However, these reporting schemes can obscure the true number of target sites that can be targeted by the system or the prediction of off-target effects by discarding or masking less active functional PAMs. One workaround is reporting multiple consensus sequences that are classified as more or less active [61], although this scheme still misses the full range of functional PAM sequences and activities. In cases where the PAM is relatively simple (e.g. NGG for the *S. pyogenes* Cas9) or the user is only interested in the most active PAMs, then sequence logos and consensus sequences are sufficient.

A separate scheme that better captures individual functional PAM sequences and activities can be described as a PAM table (**Figure 5B,E**). The table is similar to a codon table in

which each base of the codon appears along the edges and each of the 64 cells represents a distinct sequence. In the case of the PAM table, each cell conveys the activity or enrichment/depletion score for that specific PAM sequence. Cells with similar activities or scores can be colored, although the groupings are somewhat arbitrary. The upside of the table is that it displays all PAM sequences and activities in a relatively compact format, as illustrated for PAMs recognized by the *S. pyogenes* Cas9 and by multiple CRISPR-Cas systems present in *Pyrococcus furiosus* [59,60]. The major downside is that the table is difficult to expand beyond three bases, greatly limiting the size of a PAM library that can be reported.

We recently developed a reporting scheme called the PAM wheel that also captures individual sequences and activities that can convey larger PAM libraries [64] (**Figure 5C,F**). The PAM wheel are derived from interactive Krona plots [75]. Each PAM sequence is read by moving along a radius of the circle, where the accompanying arrow specifies the location of each base in relation to the protospacer. The relative activity of each PAM sequence scales with the size of the radial arc. The outer, black rings designate functional PAM sequences. As a Krona plot, any sector of the wheel can be expanded to better view a defined subset of sequences, such as PAMs that begin with a G. The ability to fully interrogate all possible sequences grants a comprehensive picture of the PAM landscape that is otherwise obscured by the other available reporting schemes. For instance, the PAM wheel revealed a potential two-base linker for the *S. pyogenes* Cas9 or strong base preferences at the -4 position for some functional PAM sequences for the *E. coli* Type I-E system (**Figure 5**). The most notable disadvantage is that the PAM wheel can be difficult to interpret, particularly in comparison to the other described methods. There is still room for additional reporting schemes that effectively capture and convey the higher-order

information content of the PAM, and it will be up to the CRISPR research community to settle on a common scheme or set of schemes to convey PAM sequences and activities.

PAM Engineering

While the PAM remains an essential feature for self/non-self discrimination, it also restricts which sequences can be targeted by a given CRISPR-Cas system and impacts the likelihood of off-target effects. Accordingly, there has been intense interest in modifying Cas proteins—particularly the widely used Cas9 effector proteins—to change the recognized PAM [68,72,76,77]. This interest has been fueled by the growing number of structural studies that have pinpointed the PAM-interacting domains and how these domains interact with the PAM as part of target recognition [78–80]. The PAM-interacting domains are relatively modular, allowing Nishimasu and coworkers to swap these domains between the closely related *S. pyogenes* Cas9 and *S. thermophilus* CRISPR3 Cas9 proteins, thereby changing each Cas9's PAM recognition (**Figure 6**) [45]. Rationally mutating the protein residues involved in PAM binding has proven more difficult as illustrated for the *S. pyogenes* Cas9 [9], although Anders and coworkers successfully changed PAM recognition using a variant of this protein [77].

The most successful PAM engineering efforts to-date combined random mutagenesis of the DNA binding residues or the entire protein with a high-throughput dual selection. Kleinstiver and coworkers applied this combination to change PAM recognition for the *S. pyogenes* Cas9 and the compact *Staphylococcus aureus* Cas9. These efforts generated a variant of the *S. pyogenes* Cas9 with only three point mutations (Cas9 VQR) that changed the recognized PAM from NGG to NGA. The new Cas9 exhibited a lower propensity for off-target effects for the selected targets [72] despite more promiscuous PAM recognition [64]. These efforts also generated a variant of the *S. aureus* Cas9 that relaxed its recognized PAM consensus sequence

from NNGRRT (where R is A or G) to NNNRRT [76]. Relaxing the requirement for a G did not impact the propensity for off-target effects despite the expectation that a more flexible PAM would reduce its contribution to targeting specificity [76,81]. Applying similar strategies to other Cas effector proteins such as Cpf1 could generate an expanded set of proteins that are no longer limited to their natural PAM sequences, thereby expanding the types of sequences that can be targeted for genome editing and other applications.

Shipman and coworkers recently extended PAM engineering to the acquisition proteins Cas1 and Cas2 from the *E. coli* Type I-E system [68]. These proteins function together to integrate new spacers into the CRISPR array [82–84]. While the work by Shipman and coworkers sought to utilize these proteins to incorporate synthetic spacers for long-term memory storage, the two proteins were also engineered to relax their PAM recognition requirements. The engineering was performed using error-prone PCR, followed by integrating spacers from non-canonical PAMs [68]. The resulting variants of Cas1 and Cas2 still slightly preferred an AAG PAM, although to a lesser extent than the wild-type versions. Taken together, these accomplishments highlight the potential for engineering diverse Cas effector proteins and acquisition proteins for tightened, relaxed, or non-native PAM recognition.

PERSPECTIVES

Our knowledge of what comprises a PAM has been overwhelmingly shaped by a few well-characterized Cas effector proteins. However, these few proteins stand in contrast to the large diversity of systems currently spanning 19 subtypes and thousands of individual proteins [18,19] (**Table 1**). Furthermore, characterization of different Cas9 proteins from II-A systems revealed large variation in the PAM: for instance, those for Cas9 proteins from *S. pyogenes* (NGG PAM), *S. thermophilus* (NNAGAA PAM), and *S. aureus* (NNGRRT PAM). We predict that

characterizing multiple systems within other subtypes has the potential to reveal similarly diverse PAMs. By performing bioinformatics and structural analyses of these effector proteins, we could learn how PAM recognition domains uniquely recognize different PAM sequences, informing future efforts to engineer PAM recognition. Elucidating PAMs within different subtypes could also reveal the full range extent of PAM sequences and lengths present in nature, highlighting which sequences may be more readily accessible through PAM engineering.

High-throughput methods have been invaluable tools to determine PAMs for varying CRISPR-Cas systems. One consistent insight from these methods is the plasticity of the PAM. Rather than a static sequence that is either correct or incorrect, the PAM comprises a range of sequences with varying activities. This is highlighted by the Type V-A Cpf1 effector protein from *Francisella novicida*, which has a reported PAM consensus of NTTN but exhibits clear bias within the first T and both N's [64,69,73]. Another unique insight is the co-dependency between the PAM and the protospacer. Despite the general assumption that these entities operate independently, separate studies with the Type I-E system from *E. coli* have shown that the relative activity of different PAMs depended on the specific target sequence [54,64]. Whether this co-dependency extends to other systems remains to be explored and may need to become a standard part of any attempt at high-throughput PAM determination. Finally, there is evidence that PAM determination methods can predict slightly different PAMs for the same CRISPR-Cas system. For instance, characterization of the *Streptococcus thermophilus* CRISPR1 Cas9 using an *in vivo* plasmid-clearance assay, an *in vitro* cleavage assay, and an *in vivo* binding assay revealed different suboptimal PAMs [64,71,72]. While these differences may be attributed to the selected PAM reporting schemes, they highlight how the available PAM determination methods can yield disparate results. These differences can be important, as elucidated PAMs may not be

universally relevant across all applications. As a result, it may be best to perform PAM determination methods that best align with the final application (i.e. *in vitro* cleavage assays for genome editing; binding assays for transcriptional regulation).

The ability to engineer PAM recognition holds great potential for CRISPR technologies. One potential outcome is revising the process of guide-RNA design. The current process involves identifying a PAM within a genetic locus and then selecting the flanking sequence as the target. However, PAM engineering could be used to generate a collection of effector proteins that together recognize all possible PAM sequences. For instance, the collection could include 15 derivatives of the *S. pyogenes* Cas9 that each recognize a variant of the NGG consensus PAM. Separately, the PAM could be lengthened to recognize a more specific sequence that is likely to be found across a genome. These mutations could be combined with those known to better reject mismatches between the guide RNA and the target [85,86], potentially yielding highly specific Cas effector proteins with negligible off-target effects.

ACKNOWLEDGMENTS

We thank Michelle Luo, Matthew Waller, and Rodolphe Barrangou for constructive feedback on the manuscript. The work was supported by funding from the National Science Foundation (CBET-1403135, MCB-1452902 to C.L.B.), the National Institutes of Health (1R35GM119561-01 to C.L.B., 5T32GM008776-15 to R.T.L.), and Agilent Technologies (to C.L.B.). C.L.B. and R.T.L. have submitted provisional patent applications on CRISPR technologies. C.L.B. is a co-founder of Locus Biosciences and a member of its scientific advisory board.

REFERENCES

- [1] R. Barrangou, C. Fremaux, H. Deveau, M. Richards, P. Boyaval, S. Moineau, D.A. Romero, P. Horvath, CRISPR provides acquired resistance against viruses in prokaryotes, *Science*. 315 (2007) 1709–1712. doi:10.1126/science.1138140.
- [2] J.A. Doudna, E. Charpentier, The new frontier of genome engineering with CRISPR-Cas9, *Science*. 346 (2014) 1258096. doi:10.1126/science.1258096.
- [3] P.D. Hsu, E.S. Lander, F. Zhang, Development and applications of CRISPR-Cas9 for genome engineering., *Cell*. 157 (2014) 1262–1278. doi:10.1016/j.cell.2014.05.010.
- [4] J. van der Oost, E.R. Westra, R.N. Jackson, B. Wiedenheft, Unravelling the structural and mechanistic basis of CRISPR-Cas systems., *Nat Rev Microbiol*. 12 (2014) 479–492. doi:10.1038/nrmicro3279.
- [5] R. Barrangou, J.A. Doudna, Applications of CRISPR technologies in research and beyond, *Nat. Biotechnol*. 34 (2016) 933–941. doi:10.1038/nbt.3659.
- [6] P. Mali, L. Yang, K.M. Esvelt, J. Aach, M. Guell, J.E. DiCarlo, J.E. Norville, G.M. Church, RNA-Guided human genome engineering via Cas9, *Science*. 339 (2013) 823–826. doi:10.1126/science.1232033.RNA-Guided.
- [7] L. Cong, F.A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P.D. Hsu, X. Wu, W. Jiang, L.A. Marraffini, F. Zhang, Multiplex genome engineering using CRISPR/Cas systems., *Science*. 339 (2013) 819–823. doi:10.1126/science.1231143.
- [8] D. Bikard, L.A. Marraffini, Control of gene expression by CRISPR-Cas systems, *F1000Prime Rep*. 5 (2013). doi:10.12703/p5-47.
- [9] M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J.A. Doudna, E. Charpentier, A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, *Science*. 337 (2012) 816–822. doi:10.1126/science.1225829.

- [10] M.L. Luo, A.S. Mullis, R.T. Leenay, C.L. Beisel, Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression., *Nucleic Acids Res.* 43 (2014) 674–681. doi:10.1093/nar/gku971.
- [11] K.M. Esvelt, A.L. Smidler, F. Catteruccia, G.M. Church, Concerning RNA-guided gene drives for the alteration of wild populations, *Elife*. e03401 (2014). doi:10.7554/eLife.03401.
- [12] A. Hammond, R. Galizi, K. Kyrou, A. Simoni, C. Siniscalchi, D. Katsanos, M. Gribble, D. Baker, E. Marois, S. Russell, A. Burt, N. Windbichler, A. Crisanti, T. Nolan, A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector *Anopheles gambiae*, *Nat. Biotechnol.* 34 (2016) 78–83. doi:10.1038/nbt.3439.
- [13] D. Bikard, C.W. Euler, W. Jiang, P.M. Nussenzweig, G.W. Goldberg, X. Duportet, V.A. Fischetti, L.A. Marraffini, Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials., *Nat. Biotechnol.* 32 (2014) 1146–1150. doi:10.1038/nbt.3043.
- [14] A.A. Gomaa, H.E. Klumpe, M.L. Luo, K. Selle, R. Barrangou, C. Beisel, Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems, *MBio*. 5 (2014). doi:10.1128/mBio.00928-13.
- [15] T. Anton, S. Bultmann, H. Leonhardt, Y. Markaki, Visualization of specific DNA sequences in living mouse embryonic stem cells with a programmable fluorescent CRISPR/Cas system., *Nucleus*. 5 (2014) 163–172. doi:10.4161/nucl.28488.
- [16] B. Chen, L. a Gilbert, B. a Cimini, J. Schnitzbauer, W. Zhang, G. Li, J. Park, E.H. Blackburn, J.S. Weissman, S. Lei, Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system, *Cell*. 155 (2013) 1479–1491. doi:10.1016/j.cell.2013.12.001.Dynamic.

- 437 [17] P. Mohanraju, K.S. Makarova, B. Zetsche, F. Zhang, E.V. Koonin, J. Van der Oost,
438 Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems,
439 Science. 353 (2016) aad5147. doi:10.1126/science.aad5147.
- 440 [18] K.S. Makarova, Y.I. Wolf, O.S. Alkhnbashi, F. Costa, S.A. Shah, S.J. Saunders, R.
441 Barrangou, S.J.J. Brouns, E. Charpentier, D.H. Haft, P. Horvath, S. Moineau, F.J.M.
442 Mojica, R.M. Terns, M.P. Terns, M.F. White, A.F. Yakunin, R.A. Garrett, J. van der Oost,
443 R. Backofen, E. V. Koonin, An updated evolutionary classification of CRISPR–Cas
444 systems, Nat. Rev. Microbiol. 13 (2015) 722–736. doi:10.1038/nrmicro3569.
- 445 [19] S. Shmakov, O.O. Abudayyeh, K.S. Makarova, Y.I. Wolf, J.S. Gootenberg, E. Semenova,
446 L. Minakhin, J. Joung, S. Konermann, K. Severinov, F. Zhang, E. V. Koonin, Discovery
447 and functional characterization of diverse class 2 CRISPR-Cas systems, Mol. Cell. 60
448 (2015) 1–13. doi:10.1016/j.molcel.2015.10.008.
- 449 [20] M.L. Luo, R.T. Leenay, C.L. Beisel, Current and future prospects for CRISPR-based tools
450 in bacteria, Biotechnol. Bioeng. 113 (2016) 930–943. doi:10.1002/bit.25851.
- 451 [21] P. Horvath, D.A. Romero, A.-C. Coute-Monvoisin, M. Richards, H. Deveau, S. Moineau,
452 P. Boyaval, C. Fremaux, R. Barrangou, Diversity, activity, and evolution of CRISPR loci
453 in *Streptococcus thermophilus*, J. Bacteriol. 190 (2008) 1401–1412.
454 doi:10.1128/JB.01415-07.
- 455 [22] H. Deveau, R. Barrangou, J.E. Garneau, J. Labonte, C. Fremaux, P. Boyaval, D.A.
456 Romero, P. Horvath, S. Moineau, Phage response to CRISPR-encoded resistance in
457 *Streptococcus thermophilus*, J. Bacteriol. 190 (2008) 1390–1400. doi:10.1128/JB.01412-
458 07.
- 459 [23] F.J.M. Mojica, C. Diez-Villasenor, J. Garcia-Martinez, C. Almendros, Short motif

- sequences determine the targets of the prokaryotic CRISPR defence system,
Microbiology. 155 (2009) 733–740. doi:10.1099/mic.0.023960-0.
- [24] J.E. Garneau, M.-È. Dupuis, M. Villion, D. a Romero, R. Barrangou, P. Boyaval, C. Fremaux, P. Horvath, A.H. Magadán, S. Moineau, The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA., Nature. 468 (2010) 67–71. doi:10.1038/nature09523.
- [25] G. Gasiunas, R. Barrangou, P. Horvath, V. Siksnys, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria., Proc. Natl. Acad. Sci. U. S. A. 109 (2012) E2579-86. doi:10.1073/pnas.1208507109.
- [26] C.R. Hale, P. Zhao, S. Olson, M.O. Duff, B.R. Graveley, L. Wells, R.M. Terns, M.P. Terns, RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex, Cell. 139 (2009) 945–956. doi:10.1016/j.cell.2009.07.040.
- [27] M. Jinek, A. East, A. Cheng, S. Lin, E. Ma, J. Doudna, RNA-programmed genome editing in human cells, Elife. 2013 (2013) 1–9. doi:10.7554/eLife.00471.
- [28] M.M. Jore, M. Lundgren, E. van Duijn, J.B. Bultema, E.R. Westra, S.P. Waghmare, B. Wiedenheft, Ü. Pul, R. Wurm, R. Wagner, M.R. Beijer, A. Barendregt, K. Zhou, A.P.L. Snijders, M.J. Dickman, J.A. Doudna, E.J. Boekema, A.J.R. Heck, J. van der Oost, S.J.J. Brouns, Structural basis for CRISPR RNA-guided DNA recognition by Cascade, Nat. Struct. Mol. Biol. 18 (2011) 529–536. doi:10.1038/nsmb.2019.
- [29] E.R. Westra, P.B.G. van Erp, T. Künne, S.P. Wong, R.H.J. Staals, C.L.C. Seegers, S. Bollen, M.M. Jore, E. Semenova, K. Severinov, W.M. de Vos, R.T. Dame, R. de Vries, S.J.J. Brouns, J. van der Oost, CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3., Mol. Cell. 46

483 (2012) 595–605. doi:10.1016/j.molcel.2012.03.018.

484 [30] F.J.M. Mojica, C. Díez-Villaseñor, J. García-Martínez, E. Soria, Intervening sequences of
485 regularly spaced prokaryotic repeats derive from foreign genetic elements, J. Mol. Evol.
486 60 (2005) 174–182. doi:10.1007/s00239-004-0046-3.

487 [31] R. Jansen, J.D.A. Van Embden, W. Gaastra, L.M. Schouls, Identification of genes that are
488 associated with DNA repeats in prokaryotes, Mol. Microbiol. 43 (2002) 1565–1575.
489 doi:10.1046/j.1365-2958.2002.02839.x.

490 [32] A. Bolotin, B. Quinquis, A. Sorokin, S. Dusko Ehrlich, Clustered regularly interspaced
491 short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin,
492 Microbiology. 151 (2005) 2551–2561. doi:10.1099/mic.0.28048-0.

493 [33] J. Carte, R. Wang, H. Li, R.M. Terns, M.P. Terns, Cas6 is an endoribonuclease that
494 generates guide RNAs for invader defense in prokaryotes, Genes Dev. 22 (2008) 3489–
495 3496. doi:10.1101/gad.1742908.

496 [34] S.J.J. Brouns, M.M. Jore, M. Lundgren, E.R. Westra, R.J.H. Slijkhuis, A.P.L. Snijders,
497 M.J. Dickman, K.S. Makarova, E. V. Koonin, J. van der Oost, Small CRISPR RNAs
498 guide antiviral defense in prokaryotes, Science. 321 (2008) 960–964.
499 doi:10.1126/science.1159689.

500 [35] E. Deltcheva, K. Chylinski, C.M. Sharma, K. Gonzales, CRISPR RNA maturation by
501 *trans*-encoded small RNA and host factor RNase III, Nature. 471 (2011) 602–607.
502 doi:10.1038/nature09886.CRISPR.

503 [36] D. Burstein, C.L. Sun, C.T. Brown, I. Sharon, K. Anantharaman, A.J. Probst, B.C.
504 Thomas, J.F. Banfield, Major bacterial lineages are essentially devoid of CRISPR-Cas
505 viral defence systems., Nat. Commun. 7 (2016) 10613. doi:10.1038/ncomms10613.

- 506 [37] K.S. Makarova, D.H. Haft, R. Barrangou, S.J.J. Brouns, E. Charpentier, P. Horvath, S.
507 Moineau, F.J.M. Mojica, Y.I. Wolf, A.F. Yakunin, J. van der Oost, E. V. Koonin,
508 Evolution and classification of the CRISPR–Cas systems, *Nat. Rev. Microbiol.* 9 (2011)
509 467–477. doi:10.1038/nrmicro2577.
- 510 [38] K. Chylinski, K.S. Makarova, E. Charpentier, E. V. Koonin, Classification and evolution
511 of type II CRISPR-Cas systems, *Nucleic Acids Res.* 42 (2014) 6091–6105.
512 doi:10.1093/nar/gku241.
- 513 [39] O.O. Abudayyeh, J.S. Gootenberg, S. Konermann, J. Joung, I.M. Slaymaker, D.B. Cox, S.
514 Shmakov, K.S. Makarova, E. Semenova, L. Minakhin, K. Severinov, A. Regev, E.S.
515 Lander, E. V Koonin, F. Zhang, C2c2 is a single-component programmable RNA-guided
516 RNA-targeting CRISPR effector, *Science*. 353 (2016) aaf5573. doi:10.1101/054742.
- 517 [40] J.R. Elmore, N.F. Sheppard, N. Ramia, T. Deighan, H. Li, R.M. Terns, M.P. Terns,
518 Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR–
519 Cas system, *Genes Dev.* 30 (2016) 447–459. doi:10.1101/gad.272153.115.
- 520 [41] L.A. Marraffini, E.J. Sontheimer, Self versus non-self discrimination during CRISPR
521 RNA-directed immunity, *Nature*. 463 (2010) 568–571. doi:10.1038/nature08703.
- 522 [42] B. Wiedenheft, E. van Duijn, J.B. Bultema, S.P. Waghmare, K. Zhoua, A. Barendregt, W.
523 Westphal, A.J.R. Heck, E.J. Boekema, M.J. Dickman, J. Douda, RNA-guided complex
524 from a bacterial immune system enhances target recognition through seed sequence
525 interactions, *Proc. Natl. Acad. Sci.* 108 (2011) 15010–15010.
526 doi:10.1073/pnas.1111854108.
- 527 [43] S. Mulepati, A. Héroux, S. Bailey, Crystal structure of a CRISPR RNA-guided
528 surveillance complex bound to a ssDNA target., *Science*. 345 (2014) 1479–1484.

doi:10.1126/science.1256996.

[44] M. Jinek, F. Jiang, D.W. Taylor, S.H. Sternberg, E. Kaya, E. Ma, C. Anders, M. Hauer, K. Zhou, S. Lin, M. Kaplan, A.T. Iavarone, E. Charpentier, E. Nogales, J.A. Doudna, Structures of Cas9 endonucleases reveal RNA-mediated conformational activation., Science. 343 (2014) 1247997. doi:10.1126/science.1247997.

[45] H. Nishimasu, F.A. Ran, P.D. Hsu, S. Konermann, S.I. Shehata, N. Dohmae, R. Ishitani, F. Zhang, O. Nureki, Crystal structure of Cas9 in complex with guide RNA and target DNA, Cell. 156 (2014) 935–949. doi:10.1016/j.cell.2014.02.001.

[46] C. Anders, O. Niewoehner, A. Duerst, M. Jinek, Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease., Nature. 513 (2014) 569–573. doi:10.1038/nature13579.

[47] S.H. Sternberg, S. Redding, M. Jinek, E.C. Greene, J. Doudna, DNA interrogation by the CRISPR RNA-guided endonuclease Cas9, Nature. 507 (2014) 62–67. doi:10.1038/nature13011.

[48] I. Yosef, D. Shitrit, M.G. Goren, D. Burstein, T. Pupko, U. Qimron, DNA motifs determining the efficiency of adaptation into the *Escherichia coli* CRISPR array., Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 14396–401. doi:10.1073/pnas.1300108110.

[49] E. Savitskaya, E. Semenova, V. Dedkov, A. Metlitskaya, K. Severinov, High-throughput analysis of type I-E CRISPR/Cas spacer acquisition in *E. coli*, RNA Biol. 10 (2013) 716–725. doi:10.4161/rna.24325.

[50] A. Levy, M.G. Goren, I. Yosef, O. Auster, M. Manor, G. Amitai, R. Edgar, U. Qimron, R. Sorek, CRISPR adaptation biases explain preference for acquisition of foreign DNA, Nature. 520 (2015) 505–510. doi:10.1038/nature14302.

552 [51] R. Heler, P. Samai, J.W. Modell, C. Weiner, G.W. Goldberg, D. Bikard, L.A. Marraffini,
553 Cas9 specifies functional viral targets during CRISPR-Cas adaptation, *Nature*. 519 (2015)
554 1–16. doi:10.1038/nature14245.

555 [52] Y. Wei, R.M. Terns, M.P. Terns, M.P. Terns, M.P. Terns, Cas9 function and host genome
556 sampling in type II-A CRISPR–cas adaptation, *Genes Dev.* 29 (2015) 356–361.
557 doi:10.1101/gad.257550.114.

558 [53] T. Kunne, S.N. Kieper, J.W. Bannenberg, M. Depken, M. Suarez-diez, S.J.J. Brouns, T.
559 Ku, S.N. Kieper, J.W. Bannenberg, A.I.M. Vogel, W.R. Miellet, M. Klein, Cas3-derived
560 target DNA degradation fragments fuel primed CRISPR adaptation, *Mol. Cell.* 63 (2016)
561 852–864. doi:10.1016/j.molcel.2016.07.011.

562 [54] C. Xue, A.S. Seetharam, O. Musharova, K. Severinov, S.J.J. Brouns, A.J. Severin, D.G.
563 Sashital, CRISPR interference and priming varies with individual spacer sequences,
564 *Nucleic Acids Res.* 43 (2015) 10831–10847. doi:10.1093/nar/gkv1259.

565 [55] C. Xue, N.R. Whitis, D.G. Sashital, C. Xue, N.R. Whitis, D.G. Sashital, Conformational
566 control of Cascade interference and priming activities in CRISPR immunity, *Mol. Cell.* 64
567 (2016) 1–9. doi:10.1016/j.molcel.2016.09.033.

568 [56] F.J.M. Mojica, C. Díez-Villaseñor, Right of admission reserved, no matter the path,
569 *Trends Microbiol.* 21 (2013) 446–448. doi:10.1016/j.tim.2013.06.003.

570 [57] S. Shah, S. Erdmann, F. Mojica, R. Garrett, Protospacer recognition motifs: mixed
571 identities and functional diversity, *RNA Biol.* 10 (2013) 891–899. doi:10.4161/rna.23764.

572 [58] E. Semenova, M.M. Jore, K.A. Datsenko, A. Semenova, E.R. Westra, B. Wanner, J. van
573 der Oost, S.J.J. Brouns, K. Severinov, Interference by clustered regularly interspaced short
574 palindromic repeat (CRISPR) RNA is governed by a seed sequence., *Proc. Natl. Acad.*

575 Sci. U. S. A. 108 (2011) 10098–10103. doi:10.1073/pnas.1104144108.

576 [59] J. Elmore, T. Deighan, J. Westpheling, R.M. Terns, M.P. Terns, DNA targeting by the
577 type I-G and type I-A CRISPR–Cas systems of *Pyrococcus furiosus*, Nucleic Acids Res.
578 43 (2015) gkv1140. doi:10.1093/nar/gkv1140.

579 [60] W. Jiang, D. Bikard, D. Cox, F. Zhang, L.A. Marraffini, RNA-guided editing of bacterial
580 genomes using CRISPR-Cas systems, Nat. Biotechnol. 31 (2013) 233–239.
581 doi:10.1038/nbt.2508.

582 [61] K.M. Esvelt, P. Mali, J.L. Braff, M. Moosburner, S.J. Yaung, G.M. Church, Orthogonal
583 Cas9 proteins for RNA-guided gene regulation and editing., Nat. Methods. 10 (2013)
584 1116–1121. doi:10.1038/nmeth.2681.

585 [62] A.E. Briner, P.D. Donohoue, A.A. Gomaa, K. Selle, E.M. Slorach, C.H. Nye, R.E.
586 Haurwitz, C.L. Beisel, A.P. May, R. Barrangou, Guide RNA functional modules direct
587 Cas9 activity and orthogonality, Mol. Cell. 56 (2014) 333–339.
588 doi:10.1016/j.molcel.2014.09.019.

589 [63] E.R. Westra, E. Semenova, K.A. Datsenko, R.N. Jackson, B. Wiedenheft, K. Severinov,
590 S.J.J. Brouns, Type I-E CRISPR-cas systems discriminate target from non-target DNA
591 through base pairing-independent PAM recognition., PLoS Genet. 9 (2013) e1003742.
592 doi:10.1371/journal.pgen.1003742.

593 [64] R.T. Leenay, K.R. Maksimchuk, R.A. Slotkowski, R.N. Agrawal, A.A. Gomaa, A.E.
594 Briner, R. Barrangou, C.L. Beisel, Identifying and visualizing functional PAM diversity
595 across CRISPR-Cas systems, Mol. Cell. 62 (2016) 137–147.
596 doi:10.1016/j.molcel.2016.02.031.

597 [65] F.A. Ran, L. Cong, W.X. Yan, D. a. Scott, J.S. Gootenberg, A.J. Kriz, B. Zetsche, O.

598 Shalem, X. Wu, K.S. Makarova, E. V. Koonin, P. a. Sharp, F. Zhang, *In vivo* genome
 599 editing using *Staphylococcus aureus* Cas9, Nature. 520 (2015) 186–190.
 600 doi:10.1038/nature14299.

601 [66] S.F. Altschul, W. Gish, W. Miller, E.W. Myers, D.J. Lipman, Basic local alignment search
 602 tool., J. Mol. Biol. 215 (1990) 403–10. doi:10.1016/S0022-2836(05)80360-2.

603 [67] A. Biswas, J.N. Gagnon, S.J.J. Brouns, P.C. Fineran, C.M. Brown, CRISPRTarget:
 604 Bioinformatic prediction and analysis of crRNA targets, RNA Biol. 10 (2013) 817–827.
 605 doi:10.4161/rna.24046.

606 [68] S.L. Shipman, S.L. Shipman, J. Nivala, J.D. Macklis, G.M. Church, Molecular recordings
 607 by directed CRISPR spacer acquisition, Science. 1175 (2016) 1–16.
 608 doi:10.1126/science.aaf1175.

609 [69] B. Zetsche, J.S. Gootenberg, O.O. Abudayyeh, I.M. Slaymaker, K.S. Makarova, P.
 610 Essletzbichler, S.E. Volz, J. Joung, J. van der Oost, A. Regev, E. V. Koonin, F. Zhang,
 611 Cpf1 Is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system, Cell. 163
 612 (2015) 1–13. doi:10.1016/j.cell.2015.09.038.

613 [70] V. Pattanayak, S. Lin, J.P. Guilinger, E. Ma, J.A. Doudna, D.R. Liu, High-throughput
 614 profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity,
 615 Nat. Biotechnol. 31 (2013) 839–843. doi:10.1038/nbt.2673.

616 [71] T. Karvelis, G. Gasiunas, J. Young, G. Bigelyte, A. Silanskas, M. Cigan, V. Siksnys,
 617 Rapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence elements,
 618 Genome Biol. 16 (2015) 253. doi:10.1186/s13059-015-0818-7.

619 [72] B.P. Kleinstiver, M.S. Prew, S.Q. Tsai, V. V. Topkar, N.T. Nguyen, Z. Zheng, A.P.W.
 620 Gonzales, Z. Li, R.T. Peterson, J.-R.J. Yeh, M.J. Aryee, J.K. Joung, Engineered CRISPR-

621 Cas9 nucleases with altered PAM specificities, *Nature*. 523 (2015) 481–485.
622 doi:10.1038/nature14592.

623 [73] I. Fonfara, H. Richter, M. Bratovič, A. Le Rhun, E. Charpentier, The CRISPR-associated
624 DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA, *Nature*. (2016) 1–
625 19. doi:10.1038/nature17945.

626 [74] E.A. Boyle, J.O.L. Andreasson, M. Lauren, S.H. Sternberg, M.J. Wu, K. Chantal, J.A.
627 Doudna, W.J. Greenleaf, High-throughput biochemical profiling reveals Cas9 off- target
628 binding and unbinding heterogeneity, *bioRxiv*. (2016). doi:10.1101/059782.

629 [75] B.D. Ondov, N.H. Bergman, A.M. Phillippy, Interactive metagenomic visualization in a
630 Web browser, *BMC Bioinformatics*. 12 (2011). doi:10.1186/1471-2105-12-385.

631 [76] B.P. Kleinstiver, M.S. Prew, S.Q. Tsai, N.T. Nguyen, V. V Topkar, Z. Zheng, J.K. Joung,
632 Broadening the targeting range of *Staphylococcus aureus* CRISPR-Cas9 by modifying
633 PAM recognition., *Nat. Biotechnol*. 33 (2015) 1–7. doi:10.1038/nbt.3404.

634 [77] C. Anders, K. Bargsten, M. Jinek, Structural plasticity of PAM recognition by engineered
635 variants of the RNA-guided endonuclease Cas9, *Mol. Cell*. 61 (2016) 895–902.
636 doi:10.1016/j.molcel.2016.02.020.

637 [78] D. Dong, K. Ren, X. Qiu, J. Zheng, M. Guo, X. Guan, H. Liu, N. Li, B. Zhang, D. Yang,
638 C. Ma, S. Wang, D. Wu, Y. Ma, S. Fan, J. Wang, N. Gao, Z. Huang, The crystal structure
639 of Cpf1 in complex with CRISPR RNA, *Nature*. (2016) 1–16. doi:10.1038/nature17944.

640 [79] H. Nishimasu, L. Cong, X. Winston, H. Nishimasu, L. Cong, W.X. Yan, F.A. Ran, B.
641 Zetsche, Y. Li, Crystal structure of *Staphylococcus aureus* Cas9, *Cell*. 162 (2015) 1113–
642 1126. doi:10.1016/j.cell.2015.08.007.

643 [80] R.N. Jackson, S.M. Golden, P.B.G. van Erp, J. Carter, E.R. Westra, S.J.J. Brouns, J. van

644 der Oost, T.C. Terwilliger, R.J. Read, B. Wiedenheft, Crystal structure of the CRISPR
645 RNA-guided surveillance complex from *Escherichia coli*, *Science*. 345 (2014) 1473–1479.
646 doi:10.1126/science.1256328.

647 [81] S.Q. Tsai, Z. Zheng, N.T. Nguyen, M. Liebers, V. V Topkar, V. Thapar, N. Wyvekens, C.
648 Khayter, A.J. Iafrate, L.P. Le, M.J. Aryee, J.K. Joung, GUIDE-seq enables genome-wide
649 profiling of off-target cleavage by CRISPR-Cas nucleases, *Nat Biotechnol*. 33 (2015)
650 187–197. doi:10.1038/nbt.3117.

651 [82] I. Yosef, M.G. Goren, U. Qimron, Proteins and DNA elements essential for the CRISPR
652 adaptation process in *Escherichia coli*, *Nucleic Acids Res*. 40 (2012) 5569–5576.
653 doi:10.1093/nar/gks216.

654 [83] J.K. Nuñez, P.J. Kranzusch, J. Noeske, A. V Wright, C.W. Davies, J.A. Doudna, Cas1-
655 Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive
656 immunity., *Nat. Struct. Mol. Biol*. 21 (2014) 528–534. doi:10.1038/nsmb.2820.

657 [84] K. a. Datsenko, K. Pougach, A. Tikhonov, B.L. Wanner, K. Severinov, E. Semenova,
658 Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial
659 immunity system, *Nat. Commun*. 3 (2012) 945. doi:10.1038/ncomms1937.

660 [85] B.P. Kleinstiver, V. Pattanayak, M.S. Prew, S.Q. Tsai, N.T. Nguyen, Z. Zheng, J. Keith
661 Joung, High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target
662 effects, *Nature*. 529 (2016) 490–495. doi:10.1038/nature16526.

663 [86] I.M. Slaymaker, L. Gao, B. Zetsche, D.A. Scott, W.X. Yan, F. Zhang, Rationally
664 engineered Cas9 nucleases with improved specificity, *Science*. 351 (2015) 84–88.
665 doi:10.1126/science.aad5227.

666 [87] P. Boudry, E. Semenova, M. Monot, K.A. Datsenko, A. Lopatina, O. Sekulovic, M.

667 Ospina-Bedoya, L.-C.F.K. Severinov, B. Dupuy, O. Soutourinaa, Function of the
 668 CRISPR-Cas System of the human pathogen *Clostridium difficile*, MBio. 6 (2015) 1–16.
 669 doi:10.1128/mBio.01112-15.Editor.
 670 [88] K.C. Cady, J. Bondy-Denomy, G.E. Heussler, A.R. Davidson, G.A. O’Toole, The
 671 CRISPR/Cas adaptive immune system of *Pseudomonas aeruginosa* mediates resistance to
 672 naturally occurring and engineered phages, J. Bacteriol. 194 (2012) 5728–5738.
 673 doi:10.1128/JB.01184-12.
 674 [89] G. Crooks, G. Hon, J. Chandonia, S. Brenner, WebLogo: A sequence logo generator,
 675 Genome Res. 14 (2004) 1188–1190. doi:10.1101/gr.849004.1.
 676
 677

BOXES

Box 1. Standardizing the orientation of the CRISPR PAM. The PAM sequence flanks the protospacer within the target DNA. Because of the double-stranded nature of DNA, only one strand needs to be reported along with its location relative to the protospacer. To date, both strands have been used to report PAM sequences, where the selected strand often trends with the particular type of CRISPR-Cas system. The problems are that consensus PAM sequences are reported without the orientation, and the use of either strand creates confusion about the exact location of the PAMs. Here, we describe both orientations, which we term target-centric and guide-centric, and argue for the guide-centric orientation to be universally adopted. Both orientations are illustrated in **Figure 2**. Under the target-centric orientation, the PAM is located on the same strand that base pairs with the guide RNA. In many cases, the PAM on this strand is specifically recognized by the Cas effector proteins [43,58], lending a mechanistic argument to this orientation. The target-centric orientation is regularly employed for Type I systems [29,43,58,59]. Under the guide-centric orientation, the PAM is located on the strand that matches the sequence guide RNA. This match lends to guide-RNA design, where the sequence flanking the identified PAM is used to create the guide portion of the RNA. This orientation is used for Type II and V systems [21–23,61,69]. While the two orientations are equivalent, we propose the universal adoption of the guide-centric orientation: the Cas9 effector proteins from Type II systems are the most widely recognized and published, and the PAMs for these proteins are always reported in the guide-centric orientation. Adopting this orientation would therefore have a smaller impact on the existing body of CRISPR literature.

FIGURE LEGENDS

Figure 1. Function of the CRISPR PAM. CRISPR-Cas systems naturally utilize PAMs to discriminate between self and non-self. The spacer portion of the CRISPR RNA is perfectly complementary to both its own CRISPR array (self) and the protospacer within the foreign invader's genetic material (non-self). The systems differentiate between these two through the flanking PAM that is absent within the CRISPR array (gray) and present within the invader's genetic material (red). Because the PAM is essential for target recognition, the CRISPR-Cas systems will target the invader's genetic material but not the CRISPR array.

Figure 2. Two orientations for reporting PAM sequences. The PAM sequence is located within double-stranded DNA, where either strand of the PAM can be reported along with its location relative to the protospacer. Under the target-centric orientation, the PAM is reported from the strand that base pairs with the guide RNA. Under the guide-centric orientation, the PAM is reported from the strand that matches the guide RNA and is used for guide-RNA design.

Figure 3. PAM orientation and targets for different types of CRISPR-Cas systems. CRISPR-Cas systems are subdivided into two classes and six types. Representative illustrations of the effector proteins for each type are shown. The dsDNA orientation has been flipped from Figure 2 to accommodate the guide-centric PAM orientation. Note that the effector proteins for the V-B and V-C subtypes require a tracrRNA similar to Type II systems. For Type III and VI systems, the crRNA binds target RNAs. Type III systems cleave transcribed dsDNA due to its proximity to the RNA target [40]. Note that the mechanism by which Type III and VI systems recognize their

nucleic-acid targets are still under investigation. PAM orientations are presented for all systems except for Type IV systems, which remain uncharacterized.

Figure 4. Methods for PAM determination. **(A)** *In silico* PAM determination. A BLAST search of metagenomic databases identifies potential protospacers. Matches found on foreign nucleic acid elements from bacteriophages and plasmids are aligned to elucidate a single consensus sequence. **(B)** PAM determination through plasmid clearance. Plasmids harboring a library of potential PAM sequences are transformed into cells expressing the Cas proteins and the targeting guide RNA, and functional PAM sequences are identified based on their depletion from the library. **(C)** PAM determination through bacteriophage clearance. A library of guide RNAs are designed so their targets tile along a lytic bacteriophage genome. Guide RNAs targeting a site flanked by a functional PAM protect the bacteriophage attack, as revealed by sequencing the enriched guide RNAs and mapping their locations and flanking sequences within the bacteriophage genome. **(D)** *In vitro* PAM determination through DNA cleavage. A large PAM library is incubated with purified Cas proteins and transcribed crRNAs in a reaction buffer. Functional PAMs within this library are cleaved, and a sequencing adapter (shown in orange) can then be ligated for high-throughput sequencing. Alternatively, intact DNA can be sequenced, revealing PAM sequences that were depleted because of DNA cleavage. **(E)** *In vivo* PAM determination through DNA binding. Catalytically-dead effector proteins are targeted to a PAM library upstream of the *lac* operon regulating GFP expression. If a functional PAM sequence is present, binding by the catalytically-dead effector proteins represses expression of LacI, resulting in de-repression of GFP. Fluorescence cells are then isolated by fluorescent-activated cell sorting and sequenced.

Figure 5. Reporting the CRISPR PAM. **(A-C)** Visualizing the PAM for the *S. pyogenes* Type II-A system. The reported PAMs are based on data from the plasmid-clearance method conducted by Kleinstiver and coworkers [72]. **(D-F)** Visualizing the PAM for the *E. coli* Type I-E system. The reported PAMs are based on data from the DNA-binding method conducted by Leenay and coworkers [64]. **(A)** The consensus sequence and sequence logo. The consensus sequence represents a compilation of all highly-active functional PAM sequences. The sequence logo displays the sequence conservation of each base at each position in functional PAM sequences [89]. The red box demonstrates the PAM location assuming a guide-centric orientation (see Figure 2). **(B)** The PAM table. The table displays the enrichment or depletion scores from the conducted screen for each possible sequence. Higher values represent more active PAMs. PAMs with similar activities are colored. **(C)** The PAM wheel. Individual sequences are read following a radius of the circle. The arrow shows the orientation of each base in relation to the protospacer. The larger the radian occupied by the sequence, the greater its enrichment or depletion score. The outer ring depicts a common functional PAM sequence. PAM wheels are also available as interactive .html files [64].

Figure 6. Engineering Cas proteins with altered or relaxed PAM recognition. **(A)** Changing PAM specificity for the Cas9 effector protein. This protein was engineered to recognize an alternative PAM but not the original PAM, thereby changing which sequences can be targeted by this Cas9. **(B)** Relaxing PAM specificity for the Cas1 and Cas2 acquisition proteins. These proteins still recognize the original PAM as well as additional PAMs, thereby broadening the sequences that can be acquired with these proteins.

A

B

770

771

772

773

776

777

A

S. pyogenes Type II-A Cas9

D

E. coli Type I-E Cascade

B

Nucleotide position 2

Nucleotide position 1	Nucleotide position 2				Nucleotide position 3
	A	C	G	T	
	A AAA 1.68	ACA 1.50	AGA 3.14	ATA 2.03	
	C CAA 1.50	CCA 1.31	CGA 2.50	CTA 1.63	
	G GAA 1.85	GCA 1.87	GGA 7.00	GTA 2.64	
Nucleotide position 1	A	C	G	T	Nucleotide position 3
	A AAC 1.31	ACC 1.09	AGC 1.75	ATC 1.60	
	C CAC 1.21	CCC 1.00	CGC 1.63	CTC 1.27	
	G GAC 1.61	GCC 1.23	GGC 3.25	GTC 2.14	
	T TAC 1.60	TCC 1.25	TGC 2.53	TTC 1.99	
Nucleotide position 1	A	C	G	T	Nucleotide position 3
	A AAG 15.5	ACG 2.82	AGG 87.4	ATG 3.56	
	C CAG 6.53	CCG 1.67	CGG 74.2	CTG 2.40	
	G GAG 45.8	GCG 6.05	GGG 126.	GTG 13.2	
	T TAG 12.1	TCC 2.66	TGG 92.2	TTG 3.78	
Nucleotide position 1	A	C	G	T	Nucleotide position 3
	A AAT 1.70	ACT 1.51	AGT 2.56	ATT 2.29	
	C CAT 1.67	CCT 1.37	CGT 2.12	CTT 1.81	
	G GAT 2.15	GCT 1.93	GGT 4.00	GTT 2.92	
	T TAT 2.41	TCT 1.87	TGT 3.32	TTT 2.86	

E

Nucleotide position -2

Nucleotide position -3	Nucleotide position -2				Nucleotide position -1
	A	C	G	T	
	A AAA 16.4	ACA 0.06	AGA 0.08	ATA 3.24	
	C CAA 0.46	CCA 0.06	CGA 0.01	CTA 0.03	
	G GAA 0.73	GCA 0.05	GGA 0.12	GTA 0.09	
Nucleotide position -3	A	C	G	T	Nucleotide position -1
	A AAC 35.6	ACC 0.30	AGC 0.12	ATC 0.62	
	C CAC 0.08	CCC 0.06	CGC 0.19	CTC 0.07	
	G GAC 0.08	GCC 0.06	GGC 0.14	GTC 0.03	
	T TAC 0.14	TCC 0.03	TGC 0.02	TTC 0.04	
Nucleotide position -3	A	C	G	T	Nucleotide position -1
	A AAG 57.0	ACG 0.15	AGG 64.6	ATG 64.8	
	C CAG 0.60	CCG 0.06	CGG 0.31	CTG 0.17	
	G GAG 65.6	GCG 0.21	GGG 0.45	GTG 0.47	
	T TAG 62.0	TCG 0.11	TGG 0.74	TTG 2.54	
Nucleotide position -3	A	C	G	T	Nucleotide position -1
	A AAT 7.76	ACT 0.09	AGT 0.45	ATT 0.11	
	C CAT 0.07	CCT 0.08	CGT 0.04	CTT 0.04	
	G GAT 0.08	GCT 0.06	GGT 0.04	GTT 0.02	
	T TAT 0.15	TCT 0.03	TGT 0.03	TTT 1.20	

C

F

778

779

780

781

782